Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
To assess whether intravenously administered third-party bone marrow-derived mesenchymal
stromal cells (MSCs) are safe and have an impact on disease severity in RDEB